Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy

Summary

We sequenced the SERPINC1 gene in 26 patients (11 males) with antithrombin (AT) deficiency (22 type I, 4 type II), belonging to 18 unrelated families from Southern Italy. Heterozygous mutations were identified in 15/18 (83.3%) families. Of them, eight were novel mutations, each being identified in one family. Seven clearly cause impaired protein synthesis (four frameshift, one non-stop, one splicing and one 21bp deletion). One, present in a single patient, is a missense mutation thought to be causative because: a) it is absent in 100 chromosomes from controls; b) it involves a highly conserved amino acid, whose change is predicted to impair AT activity; c) no other mutation is present in the propositus. Severe mutations (i.e. nonsense, frameshift, deletions) were invariably identified in type I patients. In type II patients, 3/4 were missense mutations; the fourth leads to a 19 nucleotides shift in the stop codon. In addition to the type of mutation, the co-existence of other predisposing factors in most patients helps explain the severity of the present type I cases (age at first event, recurrence during prophylaxis). In the five families in which there was more than one member affected, the same genotype and a concordant clinical expression of the disease were found. We conclude that the molecular bases of AT deficiency in Southern Italy are different as compared to other geographic areas, and that molecular analysis and the study of the effect of the mutation may help predict the clinical expression of the disease.

Keywords

Antithrombin - serpins - highly conserved residues - mutations - thrombosis

• References

• 1 Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Haematologica 2005; 90: 238-246.
• 2 Bezemer ID, Bare LA, Doggen CJ. et al. Gene variants associated with deep vein thrombosis. J Am Med Assoc 2008; 299: 1306-1314.
• 3 Perry DJ, Carrel RW. Molecular Genetics of Human Antithrombin Deficiency. Hum Mutat 1996; 07: 7-22.
• 4 Simioni P, Sanson BJ, Prandoni P. et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
• 5 Sanson BJ, Simioni P, Tormene D. et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94: 3702-3706.
• 6 De Stefano V, Leone G, Mastrangelo S. et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-358.
• 7 Martinelli I, Mannucci PM, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
• 8 De Stefano V. Inherited thrombophilia and life-time risk of venous thromboembolism: is the burden reducible?. J Thromb Haemost 2004; 02: 1522-1525.
• 9 Vossen CY, Conard J, Fontcuberta J. et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 02: 1526-1532.
• 10 Vossen CY, Conard J, Fontcuberta J. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 03: 459-464.
• 11 Dentali F, Gianni M. VTE recurrence in patients with inherited deficiencies of natural anticoagulants. Thromb Haemost 2009; 101: 5-6.
• 12 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
• 13 Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost 2009; 101: 806-812.
• 14 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
• 15 Tait RC, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
• 16 Brouwer JLP, Lijfering WM, Ten Kate MK. et al. High long-term absolute risk of recurrent thromboembolism in patients with hereditary deficiencies of protein S, protein C, or antithrombin. Thromb Haemost 2009; 101: 93-99.
• 17 Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 5S1: 102-115.
• 18 Luxenbourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
• 19 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.. Thromb Haemost 1997; 77: 197-211.
• 20 Lee ST, Kim HJ, Kim DK. et al. Detection of large deletion mutations in the SER-PINC1 gene causing hereditary antithrombin deficiency by multiplex ligationdependent probe amplification (MLPA). J Thromb Haemost 2008; 06: 701-703.
• 21 Picard V, Nowak-Göttl U, Biron-Andreani C. et al. Molecular basis of antithrombin deficiency: Twenty-two novel mutation in the AT gene mutation. Hum Mutat 2006; 27: 600.
• 22 Antón AI, Teruel R, Corral J. et al. Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica 2009; 94: 589-592.
• 23 Castaldo G, Fuccio A, Cazeneuve C. et al. Detection of five rare cystic fibrosis mutations peculiar to Southern Italy: implications in screening for the disease and phenotype characterization for patients with homozygote mutations. Clin Chem 1999; 45: 957-962.
• 24 Elce A, Boccia A, Cardillo G. Three novel CFTR polymorphic repeats improve segregation analysis for cystic fibrosis. Clin Chem 2009; 55: 1372-1379.
• 25 Di Minno G, Davi G, Margaglione M. et al. Abnormally high thromboxane A2 biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanisms. J Clin Invest 1993; 92: 1400-1406.
• 26 Miyata T, Sato Y, Ishikawa J. et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res 2009; 124: 14-8.
• 27 Maclean PS, Tait R. Hereditary and acquired antithrombin deficiency. Drug 2007; 67: 1429-1440.
• 28 Bezemer ID, Bare LA, Doggen CJ. et al. Gene variants associated with deep vein thrombosis. J Am Med Assoc 2008; 299: 1306-1314.
• 29 Roldàn V, Ordonez A, Marin F. et al. Antithrombin Cambridge II (A348S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2009; 101: 483-486.
• 30 Franchini M, Mannucci PM. Interactions between genotype and phenotype in bleeding and thrombosis. Haematologica 2008; 93: 649-652.
• 31 Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 2011; (Suppl. 01) 26-34.